Therapeutic targeting of microRNAs: current status and future challenges

Key Points MicroRNAs (miRNAs) have important roles in many aspects of human diseases, and their targeted inhibition may have substantial therapeutic impact. Inhibition of miRNAs can be achieved through a variety of methods and chemically modified antisense oligonucleotides (anti-miRs) have shown the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature reviews. Drug discovery Ročník 13; číslo 8; s. 622 - 638
Hlavní autoři: Li, Zhonghan, Rana, Tariq M.
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 01.08.2014
Nature Publishing Group
Témata:
631/154/51/391/2310
631/337/384/331
692/699/255
692/699/67
692/699/75
Animals
Antisense RNA
Biomedicine
Biotechnology
Cancer Research
Drug Delivery Systems
Drug Discovery
Genetic regulation
Genetic research
Humans
Medicinal Chemistry
MicroRNAs - biosynthesis
MicroRNAs - drug effects
MicroRNAs - physiology
Molecular Medicine
Pharmacology/Toxicology
Properties
review-article
RNA Interference - drug effects
RNA Interference - physiology
ISSN:1474-1776, 1474-1784, 1474-1784
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Key Points MicroRNAs (miRNAs) have important roles in many aspects of human diseases, and their targeted inhibition may have substantial therapeutic impact. Inhibition of miRNAs can be achieved through a variety of methods and chemically modified antisense oligonucleotides (anti-miRs) have shown the most prominent effects. Targeted delivery of anti-miRs is crucial to achieve intended therapeutic effects, and further efforts are warranted to develop more efficient delivery systems. MicroRNAs (miRNAs) — 21- to 23-nucleotide single-stranded RNAs that regulate gene expression — have roles in numerous diseases, and are therefore attractive therapeutic targets. Li and Rana discuss strategies in the design of miRNA-targeting oligonucleotides with increased efficacy and improved in vivo delivery characteristics, and highlight some of the challenges that lie ahead in the clinical development of these therapeutics. MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified antisense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo . Finally, we review current progress on the clinical development of miRNA-targeting therapeutics.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1474-1776
1474-1784
1474-1784
DOI:10.1038/nrd4359